AMGN vs OTLK
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. OTLK: Outlook Therapeutics is the developer of LYTENAVA, the first and only FDA-approved ophthalmic formulation of bevacizumab for treating wet age-related macular degeneration.
Side-by-side fundamentals
| Metric | AMGN | OTLK | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $438.94 | $0.52 | |
| Market cap | $237.3B | $127M | |
| P/E as of 2026-10-20 | 27.26 | n/a | |
| Net margin FY2025, SEC XBRL | +21.0% | -4416.2% | AMGN higher |
| Gross margin FY2025, SEC XBRL | n/a | +4.0% | |
| Operating margin FY2025, SEC XBRL | +24.7% | -4744.3% | AMGN higher |
| ROE FY2025, SEC XBRL | +89.1% | n/a | |
| ROA FY2025, SEC XBRL | +8.5% | -335.9% | AMGN higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 4.90 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +9.9% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +11.8% | n/a | |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 15 | 0 | AMGN higher |
| Beta as of 2026-09-03 | 0.41 | 1.03 | |
| 1-year return as of 2026-10-20 close | +44.7% | -64.9% | AMGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.